Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:ALT 25 November 2025 - 31 January 2026

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune shares traded near $5.03 early Wednesday after closing at the same level Tuesday, with volatility elevated ahead of a key clinical update expected by year-end. The company’s valuation hinges on pemvidutide’s 48-week IMPACT Phase 2b readout for MASH, due in Q4 2025. Leadership changes and wide analyst price targets have added to market uncertainty. The stock jumped 12% intraday on Dec. 12 before retreating.
17 December 2025
·
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune shares traded around $5.29 at 16:50 UTC on Dec. 12, 2025, down 0.9% after a volatile session with heavy volume. The company is preparing for a CEO transition on Jan. 1, 2026, as investors await key pemvidutide Phase 2b data and an FDA meeting. Analyst targets and options activity are adding to the stock’s swings.
12 December 2025
··
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune closed at $5.61 on December 8, 2025, up 7% with heavy trading and high volatility, as short interest reached 30% of float. The company announced CEO Vipin Garg will step down January 1, 2026, with Chairman Jerry Durso taking over ahead of a key MASH trial readout. Analyst targets remain well above current prices despite recent revenue and EPS estimate cuts.
9 December 2025
·
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Altimmune shares traded near $5.10 on November 25, up about 20% over two weeks after Phase 2b data for lead drug pemvidutide was published in The Lancet and highlighted at AASLD. The stock remains down over 50% from its December 2024 high, with investor sentiment tempered by ongoing shareholder lawsuits and a new $400 million shelf registration.
25 November 2025
··

Stock Market Today

  • Silicon Motion (SIMO) Rises Despite Market Downturn, Strong Earnings Anticipated
    March 19, 2026, 7:45 PM EDT. Silicon Motion (SIMO) closed up 1.67% at $127.50, outperforming the S&P 500's 0.28% decline. Despite a 5.54% drop over the past month, SIMO is set for a significant earnings report, with analysts predicting $1.23 per share - a 105% year-over-year surge. Revenue is expected to reach $299.61 million, up nearly 80% from last year. Full-year projections show earnings of $5.8 per share and revenues hitting $1.27 billion, marking growth of 63% and 43% respectively. The stock holds a Zacks Rank #1 (Strong Buy), with recent upward estimate revisions signaling confidence. SIMO trades at a forward price-to-earnings (P/E) ratio of 21.61, slightly above its industry average, and maintains a PEG ratio of 0.77, matching its sector. The Computer - Integrated Systems industry ranks in the top 10%, underpinning favorable future performance prospects.
Go toTop